Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Breaking News
Hurricanes beat Islanders, advance to second round of Stanley Cup Playoffs
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Puma Biotechnology
(NQ:
PBYI
)
5.070
+0.050 (+1.00%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Puma Biotechnology
< Previous
1
2
3
4
5
6
Next >
S&P 500 Down 1%; Crude Oil Drops Sharply
November 17, 2022
U.S. stocks traded lower midway through trading, with the S&P 500 dropping around 1% on Thursday.
Via
Benzinga
Short Volatility Alert: Puma Biotechnology, Inc.
November 09, 2022
On Tuesday, shares of Puma Biotechnology, Inc. (NASDAQ: PBYI) experienced volatile short activity. After the activity, the stock price went up +3.99% to $3.26. The overall sentiment for PBYI has been...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
November 04, 2022
Gainers
Via
Benzinga
Puma Biotechnology Reports Third Quarter 2022 Financial Results
November 03, 2022
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
November 02, 2022
From
Puma Biotechnology, Inc.
Via
Business Wire
Why MediaAlpha Shares Jumped Around 30%; Here Are 112 Biggest Movers From Friday
November 07, 2022
Gainers
Via
Benzinga
Puma Biotechnology's Earnings Outlook
November 02, 2022
Puma Biotechnology (NASDAQ:PBYI) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that Puma...
Via
Benzinga
Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib in EGFR Exon 18-Mutant NSCLC at the 2022 EORTC/NCI/AACR Symposium
October 27, 2022
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
October 20, 2022
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
October 04, 2022
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
September 21, 2022
Via
Benzinga
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor
September 20, 2022
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket Trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022
September 11, 2022
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 06, 2022
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
September 02, 2022
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
August 05, 2022
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Second Quarter 2022 Financial Results
August 04, 2022
From
Puma Biotechnology, Inc.
Via
Business Wire
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
August 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results
July 21, 2022
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
July 06, 2022
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
June 07, 2022
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting
June 06, 2022
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Presents Final Results from the Biliary Tract Cohort of the Phase 2 SUMMIT ‘Basket’ Trial of Neratinib at the ASCO 2022 Annual Meeting
June 04, 2022
From
Puma Biotechnology, Inc.
Via
Business Wire
69 Biggest Movers From Friday
June 06, 2022
Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per...
Via
Benzinga
Puma Biotechnology Announces Publication of Abstracts on Neratinib for the 2022 ASCO Annual Meeting
May 26, 2022
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
May 11, 2022
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports First Quarter 2022 Financial Results
May 05, 2022
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Announces Publication of Neratinib Abstract Titles for the 2022 ASCO Annual Meeting
April 27, 2022
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results
April 21, 2022
From
Puma Biotechnology, Inc.
Via
Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
April 05, 2022
From
Puma Biotechnology, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.